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Abstract 10 
 11 
Objectives: Ingested ketogenic agents offer the potential to enhance endurance performance via the 12 
provision of an alternative exogenous, metabolically efficient, glycogen-sparing fuel (i.e. ketone 13 
bodies). This study aimed to assess the impact of combined carbohydrate and 1,3-butanediol (CHO-14 
BD) supplementation on endurance performance, blood beta-hydroxybutyrate (βHB) concentration and 15 
glycolytic activity, in comparison to carbohydrate supplementation alone (CHO). Design: Eleven male 16 
runners (age 38 ± 12 years, mass 67.3 ± 6.5 kg, height 174.5 ± 5.0 cm, V̇O2peak 64.2 ± 5.0 ml·kg-1·min-17 
1) performed two experimental trials in a randomised crossover design. Methods: Each trial consisted 18 
of 60 min of submaximal running, followed by a 5 km running time-trial (TT), and was performed 19 
following the ingestion of an energy matched ~650 ml drink (CHO-BD or CHO). Results: There was 20 
no difference in TT completion time between the trials (CHO: 1265 ± 93, CHO-BD: 1261 ± 96 s; 21 
p=0.723). However, blood βHB concentration in the CHO-BD trial was at least double that of the CHO 22 
trial at all time points following supplementation (p<0.05). While blood lactate concentration was lower 23 
in the CHO-BD versus CHO trial after 30 min submaximal exercise (CHO-BD: 1.46 ± 0.67 mmol·L-1, 24 
CHO: 1.77 ± 0.46 mmol·L-1, p=0.040), it was similar at other time points. Blood glucose concentrations 25 
were higher post-TT in the CHO-BD trial (CHO-BD: 5.83 ± 1.02 mmol·L-1, CHO: 5.26 ± 0.95 mmol·L-26 
1, p=0.015). Conclusions: An energy matched CHO-BD supplementation drink raised βHB 27 
concentration and acutely lowered blood lactate concentration, without enhancing 5km TT running 28 
performance. 29 
 30 
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Introduction 32 
Dietary manipulation and supplementation strategies can impact substrate utilisation1, a well-known 33 
determinant of endurance exercise performance. While less investigated, supplementation of ketone 34 
bodies (i.e. acetoacetate, beta-hydroxybutyrate (βHB) and acetone) can be used to enhance endurance 35 
performance2. When present in elevated concentrations, ketone bodies have been shown to be 36 
preferentially metabolised over other fuels3,4. By acting as an alternative substrate and as a signalling 37 
molecule, ketone bodies appear to modulate the mobilisation and metabolism of substrates during 38 
exercise, suppressing glycolysis, even in conditions that typically favour carbohydrate oxidation5. 39 
Hypothetically, elevated levels of ketone bodies could prove advantageous for long-duration endurance 40 
exercise, by sparing precious glucose and gluconeogenic reserves, thus allowing greater performance 41 
capacity later in exercise. 42 
 43 
Adherence to a ketogenic diet increases ketone bodies6, however its performance effects remain 44 
unproven7,8. For elite athletes, there are practical limitations to the ketogenic diet. First, moderate 45 
levels of ketosis can take several days to achieve, and long-term adherence is considered notoriously 46 
difficult, due to reasons related to adherence, palatability and gastrointestinal comfort9. Second, 47 
switching from a high carbohydrate diet to a ketogenic diet can, temporarily at least, reduce glycogen 48 
stores and the ability to oxidise carbohydrate6,10,11, which may in turn negatively impact 49 
performance12. 50 
 51 
Alternatively, ingestion of exogenous ketogenic agents (i.e. a supplement that when ingested 52 
increases levels of circulating ketone bodies) can allow ketone bodies to be absorbed directly through 53 
the gut epithelium, elevating blood ketone body concentrations without the need to maintain a strict 54 
diet, and without compromising glycogen stores. Indeed, exogenous ketogenic agents can act 55 
synergistically with glucose13. Ingestion of ketone esters (i.e. compounds that link an alcohol body to 56 
a ketone body) in combination with carbohydrate has improved 30 min time trial performance in 57 
highly trained cyclists following a 1 h fixed workload period at 75% Wmax 5. However, ketone ester 58 
supplements are currently expensive and have been reported to cause gastrointestinal side effects14. 59 
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 60 
1,3-butanediol (1,3-BD), a component part of the ketone ester used by Cox et al.5, could itself be a 61 
cost-effective alternative fuel source capable of inducing ketosis without gastrointestinal side-effects. 62 
When consumed, 1,3-BD undergoes a series of oxidation steps in the liver to produce βHB. Despite 63 
showing prolonged elevations of blood βHB concentration within 30 min of consumption in rodent 64 
models15, 1,3-BD alone, rather than as a ketone ester, is yet to be examined as a potential ergogenic 65 
supplement in humans.  66 
 67 
The purpose of the present study therefore was to investigate the effects of 1,3-BD supplementation in 68 
combination with carbohydrate (CHO-BD), in comparison to an energy matched carbohydrate only 69 
supplementation (CHO), on blood βHB concentration, lactate concentration (proxy of glycolytic 70 
activity) and endurance running performance. It was hypothesised that CHO+BD supplementation 71 
would increase blood βHB concentrations and also enhance running performance.  72 
 5 
Methods 73 
Eleven healthy male runners (age 38 ± 12 years, mass 67.3 ± 6.5 kg, height 174.5 ± 5.0 cm, V̇O2peak 74 
64.2 ± 5.0 ml·kg-1·min-1) provided written informed consent to participate in this study approved by 75 
the Loughborough University Ethics Approvals (Human Participants) Sub-committee. 76 
 77 
Participants visited the laboratory four times, for preliminary testing, a familiarisation session and two 78 
main experimental trials. Experimental trials assessed endurance running performance using a double-79 
blind, randomised crossover design. Participants performed a self-paced, pre-fatigued 5 km time trial 80 
(TT) following two experimental conditions: ingestion of a drink containing 1,3-butanediol and 81 
carbohydrates (CHO-BD) or carbohydrates only (CHO). All exercise took place in a temperature-82 
controlled chamber (20.5 ± 0.4°C, 52.5 ± 4.0% relative humidity; Weiss Gallenkamp, Loughborough, 83 
United Kingdom). 84 
 85 
Participants performed a discontinuous incremental protocol to lactate threshold (4 min stages at 86 
progressive speeds of 1 km·h-1), followed by a maximal continuous fixed-speed incremental ramp 87 
protocol (13.5 ± 0.9 km·h-1), with treadmill gradient increasing by 1% every min until volitional 88 
exhaustion. Peak oxygen uptake (V̇O2peak) was calculated as the highest sample of oxygen consumed 89 
(V̇O2) averaged over 60 s. Data from this test were used to extrapolate running speeds for subsequent 90 
trials. 91 
 92 
The familiarisation trial followed the same procedures as the experimental trials. All trials were 93 
performed in the morning at the same time of day to minimise circadian variations. 94 
 95 
Participants also followed several pre-trial standardisation practices that were replicated for each trial: 96 
1) completing a 24h food diary before the first trial and replicating before the second trial and also 97 
refraining from strenuous exercise and alcohol consumption in the 24 h prior to testing (light exercise 98 
was recorded and replicated), 2) consuming 500 mL of water 1 h before arriving, and 3) arriving 99 
following an overnight fast. All running was performed on a motorised treadmill (pulsar® 3p; 100 
 6 
h/p/cosmos, Nussdorf-Traunstein, Germany), at a 1% gradient. Trials were identical apart from the 101 
drink ingested. 102 
 103 
For each trial, upon entering the laboratory, participants provided a urine sample for assessment of 104 
osmolality (Osmocheck; Vitech Scientific, Horsham, United Kingdom) and had nude body mass 105 
measured (CFW-150; Adam Equipment Ltd, Milton Keynes, United Kingdom). After 5 min of seated 106 
rest, baseline measures of heart rate (HR) and gastrointestinal (GI) comfort were taken (0 = very 107 
comfortable to 10 = extremely uncomfortable), along with fingertip capillary blood samples using 20 108 
μl end-to-end glass tubes (EKF, Cardiff, UK) and 300 μl microvettes® (300 CB K2E; Sarsedt, 109 
Nümbrecht, Germany) containing potassium ethylenediaminetetraacetic acid anticoagulant (K+ 110 
EDTA), for later analysis of blood lactate, blood glucose and blood βHB concentrations. Participants 111 
then ingested 50% of the volume of an ~650 mL drink (exact volume dependent on composition of 112 
drink based on participant body mass), either CHO-BD or CHO. Following a further 30 min of seated 113 
rest, baseline measures were repeated and a further 25% of the drink was ingested. Participants then 114 
completed 60 min of submaximal running at a fixed speed equivalent to 75% V̇O2peak (12.6 ± 0.9 115 
km·h-1). Blood sampling was repeated after 30 min (participants stopped running for 30 s) and 60 min 116 
of submaximal running. Rating of perceived exertion (RPE), GI comfort and HR were measured 117 
every 15 min. 118 
 119 
Upon completion of the submaximal exercise, participants were given a 10 min rest period, during 120 
which they ingested the remaining 25% of the drink, before they completed the TT. Participants were 121 
told to complete the TT as fast as possible. To account for inconsistencies that can occur in 122 
accelerating from a standstill up to desired speed, participants started running from a rolling start at a 123 
speed equivalent to 80% V̇O2peak (13.5 ± 0.9 km·h-1) before self-selecting their running speed using a 124 
control panel mounted to the side of the treadmill. Verbal progress updates of distance completed 125 
were provided every 500 m for the first 4 km and every 250 m thereafter; HR and time were recorded 126 
at these time points. Participants were not verbally encouraged and were not made aware of time 127 
 7 
elapsed.  Upon completion of the TT, final measures of RPE, GI, blood lactate, glucose and βHB 128 
concentrations were taken. 129 
 130 
Participants ingested one of two isocaloric drinks. Both drinks contained 7 g.kg body mass-1 of water, 131 
1 g.kg body mass-1 of orange squash (Robinson’s, Brtivic PLC, Hertfordshire, UK) and 0.015 g.kg 132 
body mass-1 of artificial sweetener (Canderel, Merisant Company, Chicago, US) and either 133 
carbohydrate (CHO) or carbohydrate plus food grade 1,3-butanediol (CHO+BD). Each drink 134 
contained 60 g of carbohydrate (Maltodextrin; MyProtein, Northwich, UK). The CHO-BD drink also 135 
contained 0.5 g.kg body mass-1 1,3-butanediol (Product Number 02-59620; Penta Manufacturing Ltd, 136 
Livingston, USA), whilst the CHO drink contained additional carbohydrate (total carbohydrate in 137 
CHO drink: 110 ± 5 g) to create the matched calorie content. Participants were told they would be 138 
consuming a novel sports drink, but were not informed of the specific contents (i.e. containing 1,3-139 
butanediol and carbohydrate or carbohydrate only) until after completing the study.  140 
 141 
The 20 μl blood samples were analysed for glucose and lactate concentrations using a calibrated 142 
Biosen C-Line analyser (EKF, Cardiff, UK). The 300 μl samples were centrifuged at 2000 g for 5 min 143 
(accuSpin™ Micro 17 centrifuge; Fisher Scientific™, Pittsburgh, USA), from which plasma was 144 
aliquoted and analysed in duplicate for βHB concentration using an enzymatic assay (RANBUT; 145 
Randox, Crumlin, United Kingdom) and spectrophotometric measurement of absorbance (Varioskan 146 
Flash™; ThermoScientific™, Waltham, USA). 147 
 148 
Before each test, electrochemical (O2) and infrared (CO2) gas analyser calibrations were carried out 149 
using gases of known concentrations; the digital volume transducer was calibrated using a 3 L syringe 150 
(Carefusion, San Diego, USA). Participants wore a low-dead space face mask (Hans-Rudolph, Kansas 151 
City, USA), and breath-by-breath gas exchange data were collected continuously throughout the 152 
preliminary testing and submaximal component of the trials, using an automated open circuit 153 
metabolic cart (Jeager™ Vytnus™ CPX; Carefusion, San Diego, USA). Experimental trial breath-by-154 
breath data were pooled into 5 min segments for analysis: 10-15, 25-30, 40-45 and 55-60 min.  155 
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 156 
Height was measured using a wall-mounted stadiometer (Seca, Hamburg, Germany). HR was 157 
recorded using a Polar M400 heart rate monitor and Polar H7 transmitter (Polar, Kempele, Finland).  158 
 159 
Data are reported as mean ± standard deviation (SD) unless otherwise stated. Data were checked for 160 
normality of distribution using a Shapiro-Wilks test. A two-way repeated measures ANOVA was used 161 
to analyse data sets containing two factors. A Greenhouse-Geisser estimate was used to correct the 162 
degrees of freedom if the assumption of sphericity was violated. A one-way repeated measures 163 
ANOVA was used to analyse data sets containing one factor.  If a significant main effect was found, a 164 
post hoc Holm-Bonferroni corrected t-test was applied. Statistical significance was accepted when 165 
p<0.05, with analyses performed using SPSS Statistics (Version 21; IBM©, Chicago, USA). 166 
Magnitude-based inferences (MBI) were also used to identify practically substantial differences in 167 
performance using a modified statistical spreadsheet16. Effect sizes (ES), calculated from standardised 168 
change in mean (Std. ∆ Mean) from CHO-BD to CHO, were defined using Cohen’s d, with an ES 169 
<0.2 considered trivial, >0.2 small, >0.6 moderate, >1.2 large and >2.0 very large. Uncertainty is 170 
expressed as ±90% confidence limits (CL), which define the likely range of true values. Qualitative 171 
descriptors representing likelihood of effects being negative, trivial or positive are provided17; an 172 
effect was deemed unclear if it had >5% likelihood for more than one of these descriptors.  173 
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Results 174 
Urine osmolality (446 ± 290 mOsm·kg-1; 479 ± 246 mOsm·kg-1) and body mass (68.4 ± 6.8 kg; 67.3 175 
± 6.7 kg) on arrival at the laboratory were similar between CHO-BD and CHO trials, respectively 176 
(p>0.05), indicating similar hydration status between trials18. 177 
 178 
TT performances were similar in CHO-BD (1261 ± 96 s) and CHO trials (1265 ± 93 s) (p=0.723) 179 
(p>0.05; Figure 1A). Comparison using MBI revealed an unclear difference (-0.04 ± 90% CL 0.19). 180 
Pacing, defined by 1 km split times, was similar between trials (p=0.829) (Figure 1B). MBI 181 
comparison revealed very likely trivial differences 0-3 km (0-1km: 257 ± 22 vs 258 ± 23 s; 1-2km: 182 
254 ± 20 vs 253 ± 21 s; 2-3km: 254 ± 19 vs 254 ± 19 s), and unclear differences between 3-5 km (3-183 
4km: 252 ± 20 vs 253 ± 17 s; 4-5km: 245 ± 20 vs 247 ± 16 s). 184 
 185 
Blood βHB concentrations were similar between CHO-BD (0.36 ± 0.13 mmol·L-1) and CHO (0.36 ± 186 
0.06 mmol·L-1) trials at baseline (p=0.384), but blood βHB concentrations in CHO-BD trial was at 187 
least double that of the CHO trial thereafter (p<0.05). βHB concentration remained stable in CHO 188 
trial (p>0.05), but at least two-fold higher than baseline from 30 min onwards in the CHO-BD trial 189 
(p<0.05), without any additional increase thereafter (p>0.05) (Figure 2A). 190 
 191 
Blood glucose concentrations were similar across trials at baseline (p>0.05), rising ~70% after 30 min 192 
seated rest in both trials (p<0.0001). Glucose concentrations then returned to baseline after 30 min 193 
submaximal exercise (p<0.0001) in both trials. Glucose concentration was higher for the CHO-BD 194 
trial compared to the CHO trial post-TT (p=0.015) (Figure 2B). 195 
 196 
In both trials, blood lactate concentrations rose from baseline after 30 min submaximal exercise 197 
(p<0.05), when lactate concentrations were lower in the CHO-BD trial versus the CHO trial 198 
(p=0.040). Blood lactate concentrations were similar between trials at all other time points (p>0.05), 199 
peaking post-TT in both trials (p<0.0001) (Figure 2C). 200 
 201 
 10 
Heart rate, V̇O2, respiratory exchange ratio (RER), RPE and GI comfort (Table 1) were similar across 202 
trials at all time points measured (p>0.05). Furthermore, GI comfort was similar to baseline at all time 203 
points (p>0.05).  204 
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Discussion 205 
The present study demonstrated that CHO-BD supplementation did not improve 5 km TT 206 
performance compared to an energy matched carbohydrate drink. However, CHO-BD did acutely 207 
increase blood βHB concentrations higher than those observed when supplementing with medium-208 
chain triacylglycerol19 and ketone salts20, comparable with results attained after 1-3 days of fasting21, 209 
and lower than those produced through combined ketone ester and carbohydrate supplementation5.  210 
 211 
The performance findings of this study are consistent with others that have induced small to moderate 212 
elevations in blood βHB concentrations19,20,22. In contrast, ketone esters capable of inducing greater 213 
levels of ketosis (>2 mmol·L-1) have been shown to improve the performance of elite cyclists when 214 
ingested in combination with carbohydrate5. Therefore, the lack of a clear performance effect in this 215 
study may be due to insufficient ketosis and consequently a reduced ketone body utilisation. In 216 
addition, both drinks contained a minimum of 60 g of a single source of carbohydrate and therefore 217 
would likely have saturated transporters responsible for intestinal absorption23, rendering the 218 
additional carbohydrate in the CHO trial ineffective. The fact that 1,3-BD did not enhance 219 
performance by providing an additional substrate provides further evidence to suggest that the state of 220 
ketosis in this study was insufficient. However, further investigation may be warranted into the effect 221 
of CHO-BD when the carbohydrate dose is lower than 60 g·h-1. 222 
 223 
Specific comparisons of the changes in blood βHB concentration following CHO-BD seen in this 224 
study are also limited, as many of the studies showing elevations in blood βHB concentrations 225 
following the ingestion or infusion of 1,3-BD have used animal models15,24. Human studies have 226 
previously shown 1,3-BD to be a source of energy supply for humans, but failed to raise blood βHB 227 
levels with the small doses used25,26. Therefore, the finding of increased blood βHB concentration 228 
following human supplementation with 1,3-BD in the current study is novel.  229 
 230 
Blood lactate concentrations were lower after 30 min of submaximal exercise during the CHO-BD 231 
trial compared with CHO trial, while post-TT glucose concentrations in CHO-BD trials were higher 232 
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than in the CHO trial. These findings align with differences in exercising blood lactate and glucose 233 
concentrations that have been observed, to a greater magnitude, in studies comparing combined 234 
ketone ester and carbohydrate supplementation with carbohydrate only supplementation5.  Taken 235 
together these results suggest that 1,3-BD may reduce lactate formation or increase lactate clearance 236 
during submaximal exercise, which might spare glucose reserves. That said, this difference had 237 
disappeared by 60 min, suggesting any effects of 1,3-BD supplementation in this regard may be short-238 
lived. 239 
 240 
GI comfort was similar between CHO-BD and CHO trials at all time points. This is contrary to 241 
previous research investigating the effects of ketone esters where sensations of bloating, nausea, 242 
belching, intestinal cramps and general gastrointestinal discomfort have been reported5,19. In order to 243 
elicit a greater state of ketosis future work is likely to involve increasing the amount of 1,3-BD 244 
supplementation, which may increase the susceptibility to GI discomfort. 245 
 246 
The absence of any between-trial differences in RER contrasts with previous research where similar 247 
ketosis induced using the ketogenic diet reduced RER27. This discrepancy may be due to the different 248 
way endogenous and exogenous ketone bodies are formed or perhaps differences in endogenous 249 
glycogen availability. Endogenous ketone body production occurs in the liver from the adipolysis of 250 
high levels of circulating free fatty acids. In contrast, ketone bodies provided exogenously are 251 
absorbed through the gut epithelium and monocarboxylate transporters, without effecting fat 252 
oxidation28. Indeed, βHB is anti-lipolytic, part of a negative homeostatic feedback system to prevent 253 
ketoacidosis29, meaning that supplementation with exogenous ketone agents can reduce fat oxidation. 254 
Although elevated ketone body concentrations may signal to lower glucose oxidation, the impact on 255 
RER may also be masked by the stoichiometry of ketone body oxidation, producing RER values more 256 
similar to carbohydrates compared to lipids (βHB = 0.89; Acetoacetate = 1.00). Therefore, without 257 
knowledge of total ketone body storage, utilisation and excretion, it is impossible to draw definite 258 
conclusions from the reported RER values in this study.  259 
 260 
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Blood βHB concentrations in this study did not reach therapeutic levels described by Hashim and 261 
VanItallie4 of  >2 mmol·L-1. It is possible that higher levels of circulating ketone bodies, achieved 262 
through larger 1,3-BD dosing or combining 1,3-BD with other ketogenic agents, would have 263 
increased utilisation by metabolically demanding extra-hepatic tissues, and thus produced a 264 
performance effect3,21, as well as greater effect on blood βHB, glucose and lactate concentrations, as 265 
seen with studies using ketone esters5. 266 
 267 
βHB is a chiral compound with two optical isoforms: D-3HB and L-3HB; research in rodents has 268 
suggested the effect of this molecule on metabolism to be stereo-selective, meaning that D-3HB:L-269 
3HB ratio could play an important role in fuel selection. Relative glucose utilisation decreases as 270 
concentration of D-3HB increases while L-3HB has been shown to reverse the glycolytic inhibition 271 
caused by elevated D-3HB30. Within the present study, subjects consumed a formulation of 1,3-BD, 272 
which will have been broken down into either the D-3HB or L-3HB isomer (or both). Although the 273 
relative contributions of D-3HB and L-3HB were not quantified in this study, it is possible that the 1-274 
3-BD elevated both forms in relatively equal proportions; this is in contrast to esters that are >99% D-275 
3HB. 276 
 277 
With the techniques used in this study, the precise assessment of ketone body, glucose, and fatty acid 278 
metabolism cannot be determined. Although it was shown that 1,3-BD increases circulating βHB 279 
concentrations, these concentrations are not a true reflection of ketone body production, but rather a 280 
snapshot of metabolic flux, the balance between the absorption and production, and utilisation and 281 
clearance of βHB.  282 
 283 
Conclusion 284 
Despite elevating blood βHB concentrations supplementation with CHO-BD did not improve 5 km 285 
running performance following a 60 min submaximal running phase and did not alter substrate 286 
utilisation, compared with CHO only. Further research is needed to establish the ergogenic effects of 287 
ketone esters using different ketone ester type and dosing strategies. 288 
 14 
Practical Implications 289 
• 1,3-BD + CHO supplementation maintained 5km TT performance compared to CHO 290 
ingestion 291 
• 1,3-BD supplementation produced mild levels of ketosis 292 
• Ingestion of 1,3-BD with CHO did not cause symptoms of gastrointestinal discomfort  293 
 15 
Acknowledgements 294 
The authors would like to thank Matthew Whitaker, for his assistance in the collection of data. 295 
 296 
 297 
Funding 298 
This research did not receive any specific grant from funding agencies in the public, commercial or 299 
non-for-profit sectors.  300 
 16 
References 301 
1. Hawley JA, Brouns F, Jeukendrup A. Strategies to enhance fat utilisation during exercise. Sports 302 
Med 1998; 25(4);241-257. 303 
2. Pinckaers, PJ, Churchward-Venne, TA, Bailey, D et al. Ketone Bodies and Exercise Performance: 304 
The Next Magic Bullet or Merely Hype?. Sports Med 2017; 47(3):383-389. 305 
3. Little JR, Goto M, Spitzer JJ. Effect of ketones on metabolism of FFA by dog myocardium and 306 
skeletal muscle in vivo. Am J Physiol 1970; 219(5):1458-1463. 307 
4. Hashim SA, VanItallie TB. Ketone body therapy: from the ketogenic diet to the oral administration 308 
of ketone ester. J Lipid Res 2014; 55(9):1818-1826. 309 
5. Cox PJ, Kirk T, Ashmore T et al. Nutritional Ketosis Alters Fuel Preference and Thereby 310 
Endurance Performance in Athletes. Cell Metab 2016; 24(2):256-268. 311 
6. Volek JS, Freidenreich DJ, Saenz C et al. Metabolic characteristics of keto-adapted ultra-endurance 312 
runners. Metab 2016; 65(3):100-110. 313 
7. McSwiney FT, Wardrop B, Hyde PN et al. Keto-adaptation enhances exercise performance and 314 
body composition responses to training in endurance athletes. Metab. 315 
doi:10.1016/j.metabol.2017.11.016 316 
8. Burke, L.M., Ross, M.L., Garvican‐Lewis, L.A. et al. Low carbohydrate, high fat diet impairs 317 
exercise economy and negates the performance benefit from intensified training in elite race 318 
walkers. J. Physiol 2017; 595(9):2785-2807. 319 
9. Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments for epilepsy. Cochrane 320 
Database Syst Rev 2012; 14(3). doi:10.1002/14651858.CD001903.pub2 321 
10. Phinney SD, Horton ES, Sims EA et al. Capacity for moderate exercise in obese subjects after 322 
adaptation to a hypocaloric, ketogenic diet. J Clin Invest 1980: 66(5):1152-1161. 323 
11. Stellingwerff T, Spriet LL, Watt MJ et al. Decreased PDH activation and glycogenolysis during 324 
exercise following fat adaptation with carbohydrate restoration. Am J Physiol Endocrinol Metab 325 
2006; 290(2):E380-E388. 326 
12. Havemann L, West SJ, Goedecke JH et al. Fat adaptation followed by carbohydrate loading 327 
compromises high-intensity sprint performance. J App Physiol 2006; 100(1):194-202. 328 
 17 
13. Kashiwaya Y, Sato K, Tsuchiya N et al. Control of glucose utilization in working perfused rat 329 
heart. J Biol Chem 1994; 269(41):25502-25514. 330 
14. Vandoorne, T, De Smet S, Ramaekers M et al. Intake of a ketone ester drink during recovery from 331 
exercise promotes mTORC1 signaling but not glycogen resynthesis in human muscle. Front Physiol 332 
2017; 8. doi:10.3389/fphys.2017.00310. 333 
15. Kesl SL, Poff AM, Ward NP et al. Effects of exogenous ketone supplementation on blood ketone, 334 
glucose, triglyceride, and lipoprotein levels in Sprague–Dawley rats. Nutr Metab 2016; 13:9. doi: 335 
10.1186/s12986-016-0069-y. 336 
16. Hopkins WG. A new view of statistics. Internet Society for Sports Science. Retrieved from 337 
newstats.org/PostOnlyCrossover. Accessed June 2nd 2018. 338 
17. Batterham AM, Hopkins WG. Making meaningful inferences about magnitudes. Int J Sports 339 
Physiol Perform 2006; 1(1):50-57. 340 
18. Cheuvront SN, Ely BR, Kenefick RW et al. Biological variation and diagnostic accuracy of 341 
dehydration assessment markers. Am J Clin Nutr 2010; 92(3):565-573. 342 
19. Jeukendrup AE, Thielen JJ, Wagenmakers AJ et al. Effect of medium-chain triacylglycerol and 343 
carbohydrate ingestion during exercise on substrate utilization and subsequent cycling performance. 344 
Am J Clin Nutr 1998; 67(3):397-404. 345 
20. Rodger S, Plews D, Laursen P et al. The effects of an oral β-hydroxybutyrate supplement on 346 
exercise metabolism and cycling performance. J Sci Cycling 2017; 6(1): 26. 347 
21. Cahill Jr GF. Fuel metabolism in starvation. Annu Rev Nutr 2006; 26:1-22. 348 
22. Leckey JJ, Ross ML, Quod M et al. Ketone diester ingestion impairs time-trial performance in 349 
professional cyclists. Front Physiol 2017; 8:806. doi: 10.3389/fphys.2017.00806. 350 
23. Jeukendrup AE, Jentjens R. Oxidation of carbohydrate feedings during prolonged exercise: 351 
current thoughts, guidelines and directions for future research. Sports Med 2000; 29(6):407-424. 352 
24. Pilon D, Brodeur J, Plaa GL. 1, 3-Butanediol-induced increases in ketone bodies and potentiation 353 
of CCl4 hepatotoxicity. Toxicology 1986; 40(2):165-180. 354 
25. Kies C, Tobin RB, Fox HM et al. Utilization of 1, 3-butanediol and nonspecific nitrogen in human 355 
adults. J Nutr 1973; 103(8):1155-1163. 356 
 18 
26. Tobin RB, Mehlman MA, Kies C et al. Nutritional and metabolic studies in humans with 1, 3-357 
butanediol. Fed Proc 1975; 34(12):2171-2176. 358 
27. Zajac A, Poprzecki S, Maszczyk A et al. The effects of a ketogenic diet on exercise metabolism 359 
and physical performance in off-road cyclists. Nutrients 2014; 6(7):2493-2508. 360 
28. Cox PJ, Clarke K. Acute nutritional ketosis: implications for exercise performance and 361 
metabolism. Extrem Physiol Med 2014; 3:17. doi:10.1186/2046-7648-3-17  362 
29. Taggart AK, Kero J, Gan X et al. (D)-β-hydroxybutyrate inhibits adipocyte lipolysis via the 363 
nicotinic acid receptor PUMA-G. J Biol Chem 2005; 280(29):26649-26652. 364 
30. Tsai YC, Chou YC, Wu AB et al. Stereoselective effects of 3-hydroxybutyrate on glucose 365 
utilization of rat cardiomyocytes. Life Sci 2006; 78(12): 1385-1391.  366 
 19 
Tables 367 
 368 
 369 
Table 1 Heart rate, respiratory and perceptual scale results. Mean ± SD 370 
 CHO CHO-BD 
HR (b·min at TT end) 182 ± 10 183 ± 13 
VO2 during steady state (L·min-1) 46.9 ± 3.6 46.8 ± 3.1 
RER 0.89 ± 0.05 0.89 ± 0.04 
RPE (steady state mean) 12 ± 1 12 ± 1 
RPE (TT) 18 ± 1 18 ± 1 
GI comfort (mean all timepoints) 2 ± 2 2 ± 2 
  371 
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Figure Captions 372 
Figure 1. (A) Pre-fatigued 5 km time-trial performance for each trial. Individual and mean results 373 
presented. (B) 1 kilometre split times for the pre-fatigued 5km time-trial. Mean ± SD. 374 
Figure 2. Blood beta-hydroxybutyrate (A), blood glucose (B), and blood lactate (C) concentrations 375 
over the duration of each trial * denotes difference between trials, 1,2,3,4,5 denotes difference from 376 
baseline and subsequent time-points a denotes difference in CHO trial only, b denotes difference in 377 
BC+C trial only from baseline in CHO-BD trials only (p<0.05). Mean ± SD.378 
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Figure 1. (A) Pre-fatigued 5 km time-trial performance for each trial. Individual 
and mean results presented. (B) 1 kilometre split times for the pre-fatigued 5km 
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Figure 2. Blood beta-hydroxybutyrate (A), blood glucose (B), and blood lactate (C) 
concentrations over the duration of each trial * denotes difference between trials, 
1,2,3,4,5 denotes difference from baseline and subsequent time-points a denotes 
difference in CHO trial only, b denotes difference in BC+C trial only from baseline in 
CHO-BD trials only (p<0.05). Mean ± SD. 
